IN2014CN03333A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03333A
IN2014CN03333A IN3333CHN2014A IN2014CN03333A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A IN 3333CHN2014 A IN3333CHN2014 A IN 3333CHN2014A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A
Authority
IN
India
Prior art keywords
shk
potassium channel
inhibiting agent
modified
obesity
Prior art date
Application number
Other languages
English (en)
Inventor
George K Chandy
Sanjeev Kumar Upadhayay
Ping H Wang
Paolo Sassone Corsi
Kristin Lynn Eckel Mahan
Shawn Iadonato
Joseph Mukergee
Reza M Mirbolooki
Original Assignee
Univ California
Kineta One Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Kineta One Llc filed Critical Univ California
Publication of IN2014CN03333A publication Critical patent/IN2014CN03333A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN3333CHN2014 2011-10-03 2012-10-02 IN2014CN03333A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
PCT/US2012/058495 WO2013052507A1 (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number Publication Date
IN2014CN03333A true IN2014CN03333A (cg-RX-API-DMAC7.html) 2015-07-03

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3333CHN2014 IN2014CN03333A (cg-RX-API-DMAC7.html) 2011-10-03 2012-10-02

Country Status (16)

Country Link
US (2) US20150072940A1 (cg-RX-API-DMAC7.html)
EP (1) EP2763702A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014531469A (cg-RX-API-DMAC7.html)
KR (1) KR20140108518A (cg-RX-API-DMAC7.html)
CN (1) CN103987408A (cg-RX-API-DMAC7.html)
AU (1) AU2012318736A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014008065A2 (cg-RX-API-DMAC7.html)
CA (1) CA2850357A1 (cg-RX-API-DMAC7.html)
HK (1) HK1201048A1 (cg-RX-API-DMAC7.html)
IL (1) IL231873A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN03333A (cg-RX-API-DMAC7.html)
MX (1) MX2014004029A (cg-RX-API-DMAC7.html)
RU (1) RU2014117558A (cg-RX-API-DMAC7.html)
SG (1) SG11201401193XA (cg-RX-API-DMAC7.html)
TW (1) TW201321403A (cg-RX-API-DMAC7.html)
WO (1) WO2013052507A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2580233T3 (es) * 2004-10-07 2016-08-22 The Regents Of The University Of California Análogos de toxina ShK y sus usos en inhibición selectiva de canales de potasio Kv1.3
KR20140038501A (ko) * 2011-06-06 2014-03-28 키네타 원, 엘엘씨 Shk-기초된 제약학적 조성물 및 이들을 제조하고 이용하는 방법
IN2014CN03333A (cg-RX-API-DMAC7.html) 2011-10-03 2015-07-03 Univ California
CN107205948B (zh) * 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
TWI701249B (zh) 2015-03-13 2020-08-11 德商4Sc製藥公司 Kv1.3抑制劑及其醫學應用
TWI698438B (zh) 2015-03-13 2020-07-11 德商4Sc製藥公司 Kv1.3抑制劑及其醫學應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
US6077680A (en) * 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
AU8052798A (en) * 1997-09-17 1999-04-05 Bachem Bioscience, Inc. Polypeptide compositions that inhibit potassium channel activity and uses herefor
JP3207823B2 (ja) 1999-04-28 2001-09-10 リノール油脂株式会社 共役リノール酸を有効成分とする褐色脂肪増加剤
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
ES2580233T3 (es) 2004-10-07 2016-08-22 The Regents Of The University Of California Análogos de toxina ShK y sus usos en inhibición selectiva de canales de potasio Kv1.3
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2007020286A2 (en) * 2005-08-17 2007-02-22 Solvay Pharmaceuticals Gmbh Method of using potassium channel inhibiting compounds
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
IN2014CN03333A (cg-RX-API-DMAC7.html) 2011-10-03 2015-07-03 Univ California

Also Published As

Publication number Publication date
MX2014004029A (es) 2014-08-01
RU2014117558A (ru) 2015-11-10
TW201321403A (zh) 2013-06-01
KR20140108518A (ko) 2014-09-11
WO2013052507A1 (en) 2013-04-11
AU2012318736A1 (en) 2014-05-22
US9878006B2 (en) 2018-01-30
HK1201048A1 (en) 2015-08-21
IL231873A0 (en) 2014-05-28
SG11201401193XA (en) 2014-05-29
EP2763702A1 (en) 2014-08-13
US20150072940A1 (en) 2015-03-12
CA2850357A1 (en) 2013-04-11
EP2763702A4 (en) 2015-04-15
JP2014531469A (ja) 2014-11-27
BR112014008065A2 (pt) 2019-09-24
US20170095530A1 (en) 2017-04-06
CN103987408A (zh) 2014-08-13

Similar Documents

Publication Publication Date Title
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MY160894A (en) Oligosaccharide composition for treating skin diseases
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
IN2015DN00376A (cg-RX-API-DMAC7.html)
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
IN2014CN03333A (cg-RX-API-DMAC7.html)
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
MX364220B (es) Metodos de tratamientos de fibrosis.
PH12017500392A1 (en) Medical treatments based on anamorelin
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
MX2014001271A (es) Tratamiento de diabetes de tipo 2 con fty720.
UA61499U (en) massage mat